Merck, one of the world’s leading science and technology companies, is committed to advancing the development and commercialization of new medicines for patients in need. The company offers contract development and manufacturing (CDMO) services through BioReliance® End-to-End Solutions. We are a full-service biologics CDMO offering deep expertise and flexible, custom solutions at all stages of development and manufacturing for your monoclonal antibody, bispecific antibody, ADC or fusion protein. Our services span from mammalian cell line and process development to media and feed screening, master cell banking, scale up and GMP commercial drug substance manufacturing. Plus, our analytical methods development, validation and testing are all done in house.
With more than 30 years’ experience in process development and 25 years in GMP manufacturing, we’ve helped to bring more than 260 biologics to market and we have released 80+ GMP drug substance batches since 2012 over a range of molecules and scales.
“We take the time to understand our clients’ goals and make them ours. We ask questions about how fast a client needs to go and the acceptable level of risk,” explains Sébastien Ribault, Sébastien Ribault, Ph.D. VP and Head of End-to-End Solutions. “From those insights, we establish the strategy and design custom solutions, tailored to each molecule and project. Being adaptable by nature, we integrate our activities with existing or new partners involved in the project, helping to ensure streamlined progress towards every milestone.”